Penetration of 3′-amino-3′-deoxythymidine, a cytotoxic metabolite of zidovudine, into the cerebrospinal fluid of HIV-1-infected patients

Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology

Volumn 15, Issue 2, 1997, Pages 131-136

  Hoetelmans, Richard M W ^a   Kraaijeveld, Cees L ^a   Meenhorst, Pieter L ^a   Mulder, Jan W ^a   Burger, David M ^b   Koks, Cees H W ^a   Beijnen, Jos H ^a  

^a SLOTERVAART HOSPITAL   (Netherlands)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

3 Amino 3 deoxythymidine (AMT); Cerebrospinal fluid (CSF); HIV infection, Zidovudine (ZDV)

Indexed keywords

HUMAN IMMUNODEFICIENCY VIRUS 1; TRIXIS; HUMAN IMMUNODEFICIENCY VIRUS;

3' AMINO 3' DEOXYTHYMIDINE; ZIDOVUDINE;

ADULT; ARTICLE; BLOOD BRAIN BARRIER; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CEREBROSPINAL FLUID LEVEL; DRUG DISTRIBUTION; DRUG PENETRATION; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL;

EID: 0030808007     PISSN: 10779450     EISSN: None     Source Type: Journal    
DOI: 10.1097/00042560-199706010-00006     Document Type: Article

References (25)

1. Tyor WR, Wesselingh SL, Griffin JW, McArthur JC, Griffin DE. Unifying hypothesis for the pathogenesis of HIV-associated dementia complex, vacuolar myelopathy, and sensory neuropathy. J Acquir Immune Defic Syndr Hum Retrovirol 1995;9:379-88.
2. Portegies P, de Gans J, Lange JMA, et al. Declining incidence of AIDS dementia complex after introduction of zidovudine treatment. BMJ 1989;299:819-21.
3. Vago L, Castagna A, Lazzarin A, Trabattoni G, Cinque P, Costanzi G. Reduced frequency of HIV-induced brain lesions in AIDS patients treated with zidovudine. J Acquir Immune Defic Syndr 1993; 6:42-5.
4. Sidtis JJ, Gatsonis C, Price RW, et al. Zidovudine treatment of the AIDS dementia complex: results of a placebo-controlled trial. Ann Neurol 1993;33:343-9.
5. Tozzi V, Narciso P, Galgani S, et al. Effects of zidovudine in 30 patients with mild to end-stage AIDS dementia complex. AIDS 1993;7:683-92.
6. Portegies P, Enting EH, de Gans J, et al. Presentation and course of AIDS dementia complex: 10 years of follow-up in Amsterdam, The Netherlands. AIDS 1993;7:669-75.
7. Geleziunas R, Schipper HM, Wainberg MA. Pathogenesis and therapy of HIV-1 infection of the central nervous system. AIDS 1992;6:1411-26.
8. Stagg MP, Cretton EM, Kidd L, Diasio RB, Sommadossi J-P. Clinical pharmacokinetics of 3′-azido-3′-deoxythymidine (zidovudine) and catabolites with formation of a toxic catabolite, 3′-amino-3′-deoxythymidine. Clin Pharmacol Ther 1992;51:668-76.
9. Cretton EM, Xie M-Y, Bevan RJ, Goudgoan NM, Schinazi RF, Sommadossi J-P. Catabolism of 3′-azido-3′-deoxythymidine in hepatocytes and liver microsomes, with evidence of formation of 3′-amino-3′-deoxythymidine, a highly toxic catabolite for human bone marrow cells. Mol Pharmacol 1990;39:258-66.
10. Faraj A, Fowler DA, Bridges EG, Sommadossi J-P. Effects of 2′-3′-dideoxynucleosides on proliferation and differentiation of human pluripotent progenitors in liquid culture and their effects on mitochondrial DNA synthesis. Antimicrob Agents Chemother 1994;38:924-30.
11. Kedar PS, Abbotts J, Kovács T, Lesiak K, Torrence P, Wilson SH. Mechanism of HIV reverse transcriptase: enzyme-primer interaction as revealed through studies of a dNTP analogue, 3′-azido-dTTP. Biochemistry 1990;29:3603-11.
12. Cretton EM, Schinazi RF, McClure HM, Anderson DC, Sommadossi J-P. Pharmacokinetics of 3′-azido-3′-deoxythymidine and its catabolites and interactions with probenecid in rhesus monkeys. Antimicrob Agents Chemother 1991;35:801-7.
13. Zhou X-J, Sommadossi J-P. Quantification of 3′-amino-3′-deoxythymidine, a toxic catabolite of 3′-azido-3′-deoxythymidine (zidovudine) in human plasma by high-performance liquid chromatography using precolumn derivatization with fluorescamine and fluorescence detection. J Chromatogr B 1994;656:389-96.
14. Burger DM, Rosing H, Koopman FJ, et al. Determination of 3′-amino-3′-deoxythymidine, a cytotoxic metabolite of 3′-azido-3′-deoxythymidine, in human plasma by ion-pair high-performance liquid chromatography. J Chromatogr B 1993;622:235-42.
15. Burger DM, Kraaijeveld CL, Meenhorst PL, et al. Penetration of zidovudine into the cerebrospinal fluid of patients infected with human immunodeficiency virus. AIDS 1993;7:1581-7.
16. De Miranda P, Burnette TC, Good SS. Tissue distribution and metabolic disposition of zidovudine in rats. Drug Metab Dispos 1990;18:315-20.
17. Pan-Zhou XR, Cretton-Scott E, Zhou XJ, Yang MX, Lasker JM, Sommadossi J-P. Human liver microsomal cytochrome P450 and b5 act as reductases in the reductive metabolism of 3′-azido-3′-deoxythymidine to 3′-amino-3′-deoxythymidine [abstract PII-38). American Society for Clinical Pharmacology and Therapeutics, 97th annual meeting, Florida, March 1996.
18. Placidi L, Cretton EM, Placidi M, Sommadossi J-P. Reduction of 3′-azido-3′-deoxythymidine to 3′-amino-3′-deoxythymidine in human liver microsomes and its relationship to cytochrome P450. Clin Pharmacol Ther 1993;54:168-76.
19. Cretton EM, Sommadossi J-P. Reduction of 3′-azido-2′-3′-dideoxynucleosides to their 3′-amino metabolite is mediated by cytochrome P-450 and NADPH-cytochrome P-450 reductase in rat liver microsomes. Drug Metab Dispos 1993;21:946-50.
20. Eagling VA, Howe JL, Barry MJ, Back DJ. The metabolism of zidovudine by human liver microsomes in vitro: formation of 3′-amino-3′-deoxythymidine. Biochem Pharmacol 1994;48:267-76.
21. Miller N, Fox JJ. Nucleosides. XXI. Synthesis of some 3′-substituted 2′-3′-deoxyribonucleosides of thymidine and 5-methylcytosine. J Org Chem 1964;29:1772-6.
22. Lin T, Fischer PH, Prusoff WH. Effect of 3′-amino-3′-deoxythymidine on L1210 and P388 leukemias in mice. Biochem Pharmacol 1982;31:125-8.
23. Bridges EG, Faraj A, Sommadossi J-P. Inhibition of mammalian DNA polymerase-associated 3′ to 5′ exonuclease activity by 5′-monophosphates of 3′-azido-3′-deoxythymidine, and 3′-amino-3′-deoxythymidine. Biochem Pharmacol 1993;45:1571-6.
24. Hoggard PG, Veal GJ, Wild MJ, Barry MG, Back DJ. Drug interactions with zidovudine phosphorylation in vitro. Antimicrob Agents Chemother 1995;39:1376-8.
25. Chu LK, Schinazi RF, Ahn MK, Ullas GV, Gu ZP. Structure-activity relationships of pyrimidine nucleosides as antiviral agents for human immunodeficiency virus type 1 in peripheral blood mononuclear cells. J Med Chem 1989;39:612-7.